Hypothesis

Akkermansia muciniphila preserves epithelial lysosomal capacity during aging, thereby reducing the need for cells to sequester damaged proteins into protective aggregates. When A. muciniphila declines, lysosomal dysfunction rises, pushing the proteostasis network toward aggregate formation as a last‑resort containment strategy. Restoring A. muciniphila or its downstream signals should keep lysosomal proteolysis robust and lower the burden of insoluble protein deposits.

Mechanistic Rationale

A. muciniphila strengthens the mucus barrier and tight‑junction complexes (ZO‑1, Occludin, Claudin‑3) through upregulation of the ALPK1/TIFA pathway [2]. This barrier reinforcement limits translocation of microbial‑associated molecular patterns that trigger chronic low‑grade inflammation. Persistent inflammation impairs lysosomal acidification and cathepsin activity via NF‑κB‑mediated downregulation of V‑ATPase subunits [3]. By dampening this inflammatory milieu, A. muciniphila indirectly sustains lysosomal proteostasis.

Furthermore, A. muciniphila‑derived extracellular vesicles deliver bacteriocin‑like peptides that activate AMPK in enterocytes [1]. AMPK phosphorylation enhances TFEB nuclear translocation, the master regulator of lysosomal biogenesis and autophagy [2]. Thus, the bacterium couples barrier integrity to a cell‑intrinsic program that expands lysosomal capacity.

When lysosomal function falters, misfolded proteins that escape chaperone‑mediated refolding are redirected to aggresomes and eventually to insoluble aggregates—a process observed with tau and amyloid‑β in aged epithelia [3]. The hypothesis posits that A. muciniphila keeps this diversion minimal by maintaining a competent degradation route.

Testable Predictions

1. Lysosomal read‑outs – In aged mice supplemented with A. muciniphila (or its EVs), lysosomal acidity (LysoSensor signal) and cathepsin B/L activity will be higher than in controls, correlating with reduced detergent‑insoluble tau and ubiquitin‑positive aggregates in colonic epithelium.
2. Inflammation‑lysosome link – Blocking IL‑6 signaling in A. muciniphila‑depleted mice should rescue lysosomal function without altering bacterial levels, demonstrating that the bacterium’s effect is mediated via inflammation suppression.
3. TFEB dependence – Conditional knockout of TFEB in intestinal epithelial cells will abolish the protective effect of A. muciniphila on lysosomal markers and aggregate load, confirming TFEB as a necessary downstream effector.
4. Human correlation – In cohorts of older adults, fecal A. muciniphila abundance will positively correlate with lysosomal gene expression (LAMP1, LAMP2, CTSD) measured in colonic biopsies and inversely correlate with histologic aggregate scores.

Falsifiability

If A. muciniphila supplementation fails to improve lysosomal acidity or TFEB activation, or if aggregate burden remains unchanged despite restored lysosomal metrics, the hypothesis would be refuted. Conversely, demonstrating that lysosomal enhancement alone (e.g., via pharmacological TFEB agonists) mimics A. muciniphila’s aggregate‑reducing effect without altering mucus thickness would support the mechanistic chain but challenge the necessity of the bacterium itself.

Summary

By linking mucin‑driven barrier preservation to lysosomal homeostasis, this hypothesis reframes protein aggregation not as an inevitable endpoint but as a compensatory response to lysosomal insufficiency. Testing it will clarify whether bolstering A. muciniphila‑dependent lysosomal capacity can delay or prevent the formation of pathogenic protein deposits in aging tissues.